TY  - JOUR
A1  - Lux, Michael Patrick
A1  - Nabieva, Naiba
A1  - Hartkopf, Andreas
A1  - Huober, Jens
A1  - Volz, Bernhard
A1  - Ţăran, Florin-Andrei
A1  - Overkamp, Friedrich
A1  - Kolberg, Hans-Christian
A1  - Hadji, Peyman
A1  - Tesch, Hans
A1  - Häberle, Lothar
A1  - Ettl, Johannes
A1  - Lüftner, Diana
A1  - Wallwiener, Markus
A1  - Müller, Volkmar
A1  - Beckmann, Matthias Wilhelm
A1  - Belleville, Erik
A1  - Wimberger, Pauline
A1  - Hielscher, Carsten
A1  - Geberth, Matthias
A1  - Abenhardt, Wolfgang
A1  - Kurbacher, Christian M.
A1  - Würstlein, Rachel
A1  - Thomssen, Christoph
A1  - Untch, Michael
A1  - Fasching, Peter Andreas
A1  - Janni, Wolfgang
A1  - Fehm, Tanja
A1  - Wallwiener, Diethelm
A1  - Schneeweiss, Andreas
A1  - Brucker, Sara
T1  - Therapy landscape in patients with metastatic her2-positive breast cancer: Data from the praegnant real-world breast cancer registry
T2  - Cancers
N2  - This study presents comprehensive real-world data on the use of anti-human epidermal growth factor receptor 2 (HER2) therapies in patients with HER2-positive metastatic breast cancer (MBC). Specifically, it describes therapy patterns with trastuzumab (H), pertuzumab + trastuzumab (PH), lapatinib (L), and trastuzumab emtansine (T-DM1). The PRAEGNANT study is a real-time, real-world registry for MBC patients. All therapy lines are documented. This analysis describes the utilization of anti-HER2 therapies as well as therapy sequences. Among 1936 patients in PRAEGNANT, 451 were HER2-positive (23.3%). In the analysis set (417 patients), 53% of whom were included in PRAEGNANT in the first-line setting, 241 were treated with H, 237 with PH, 85 with L, and 125 with T-DM1 during the course of their therapies. The sequence PH → T-DM1 was administered in 51 patients. Higher Eastern Cooperative Oncology Group (ECOG) scores, negative hormone receptor status, and visceral or brain metastases were associated with more frequent use of this therapy sequence. Most patients received T-DM1 after treatment with pertuzumab. Both novel therapies (PH and T-DM1) are utilized in a high proportion of HER2-positive breast cancer patients. As most patients receive T-DM1 after PH, real-world data may help to clarify whether the efficacy of this sequence is similar to that in the approval study.
KW  - advanced breast cancer
KW  - metastatic
KW  - chemotherapy
KW  - antihormone therapy
KW  - HER2 c-erbB2
KW  - HER2/neu
KW  - trastuzumab
KW  - pertuzumab
KW  - T-DM1
KW  - lapatinib
Y1  - 2018
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/54334
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-543344
SN  - 2072-6694
N1  - This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
VL  - 11
IS  - 1, Art. 10
SP  - 1
EP  - 13
PB  - MDPI
CY  - Basel
ER  -